ClinicalTrials.gg
CompletedNCT03705065Updated Oct 28, 2026Results posted

Bupivacaine HCl PK and Safety in Augmentation Mammoplasty

A Phase 4 interventional study of Bupivacaine HCl in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Heron Therapeutics · Phase 4, Interventional, and Treatment

Updated Oct 28, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
310th of 364
30 · median 70
Started
2018
with 26 others
Phase 4
133 of 364
18 open now
Registered
154th of 364
by date
Lead sponsor
17 of 364
Heron Therapeutics

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 310th largest by enrollment, is one of 27 that started in 2018, is one of 133 in phase 4, and was the 154th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.

03

Conditions studied

  • Postoperative Pain

Browse trials for

Keywords

  • augmentation mammoplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is scheduled to undergo primary bilateral submuscular augmentation mammoplasty with saline or silicone smooth implants with a volume of 300 to 500 mL, inclusive.
  • Has an Physical Status of I, II, or III.
  • Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable .

Exclusion criteria

Exclusion Criteria:

  • Has a planned concurrent surgical procedure (eg, mastopexy).
  • Has a planned concurrent reconstructive procedure status post breast cancer therapy.
  • Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain that is not strictly related to the augmentation mammoplasty.
  • Has a or a known or suspected history of or idiosyncratic reaction to required study medications.
  • Has been administered bupivacaine within 5 days prior to the scheduled surgery.
  • Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
  • Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
  • As per subject history and/or medical records, has active infection or is currently undergoing treatment for , , or (HIV).
  • Has uncontrolled anxiety, psychiatric, or neurological disorder.
  • Had a in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study at the discretion of the Sponsor. Subjects taking any marijuana (medical or recreational) are not allowed to participate in the study.
  • Received an product or device in a clinical trial within 30 days or within 5 elimination half-lives.
  • Has undergone 3 or more surgeries within 12 months.
  • Has a (BMI) >35 kg/m2.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Bupivacaine HCI via instillation

    Bupivacaine HCI 150 mg via instillation (75 mg into each pectoral pocket)

    Drug: Bupivacaine HCl

  • Experimental
    Bupivacaine HCI via injection

    Bupivacaine HCI 150 mg via injection (75 mg into each pectoral pocket)

    Drug: Bupivacaine HCl

Interventions

  • Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum observed bupivacaine plasma concentration

    Time frame: Through 72 hours after start of study drug administration

  2. AUClast

    Area under the bupivacaine plasma concentration-time curve through 72 hours postdose

    Time frame: Through 72 hours after start of study drug administration

  3. AUCinf

    Area under the bupivacaine plasma concentration-time curve from the start of study drug administration extrapolated to infinity

    Time frame: Through 72 hours after start of study drug administration

  4. Tmax

    Time to maximum bupivacaine plasma concentration

    Time frame: Through 72 hours after start of study drug administration

  5. λz

    Apparent terminal elimination rate constant

    Time frame: Through 72 hours after start of study drug administration

  6. t1/2el

    Apparent terminal elimination half-life

    Time frame: Through 72 hours after start of study drug administration

07

Results

Posted Oct 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneBupivacaine HCI Via InstillationBupivacaine HCl Via Injection
Started1515
Completed1514
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryCmax

Maximum observed bupivacaine plasma concentration

Time frame:
Through 72 hours after start of study drug administration
Reported as:
Mean · ng/mL
Cmax
ng/mLBupivacaine HCI Via InstillationBupivacaine HCI Via Injection
Cmax1110 ± 3471110 ± 469
PrimaryAUClast

Area under the bupivacaine plasma concentration-time curve through 72 hours postdose

Time frame:
Through 72 hours after start of study drug administration
Reported as:
Mean · h∙ng/mL
AUClast
h∙ng/mLBupivacaine HCI Via InstillationBupivacaine HCl Via Injection
AUClast9620 ± 61908610 ± 2400
PrimaryAUCinf

Area under the bupivacaine plasma concentration-time curve from the start of study drug administration extrapolated to infinity

Time frame:
Through 72 hours after start of study drug administration
Reported as:
Mean · h∙ng/mL
AUCinf
h∙ng/mLBupivacaine HCI Via InstillationBupivacaine HCl Via Injection
AUCinf9850 ± 67608710 ± 2340
PrimaryTmax

Time to maximum bupivacaine plasma concentration

Time frame:
Through 72 hours after start of study drug administration
Reported as:
Median · hours
Tmax
hoursBupivacaine HCI Via InstillationBupivacaine HCl Via Injection
Tmax1.03 (0.53 to 1.58)0.73 (0.18 to 1.25)
Primaryλz

Apparent terminal elimination rate constant

Time frame:
Through 72 hours after start of study drug administration
Reported as:
Mean · /h
λz
/hBupivacaine HCI Via InstillationBupivacaine HCl Via Injection
λz0.0572 ± 0.01690.0963 ± 0.0227
Primaryt1/2el

Apparent terminal elimination half-life

Time frame:
Through 72 hours after start of study drug administration
Reported as:
Mean · hours
t1/2el
hoursBupivacaine HCl Via InstillationBupivacaine HCl Via Injection
t1/2el13.5 ± 5.037.69 ± 2.33

Adverse events

Collected over From the time the subject signed the Informed Consent Form through Day 28.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupivacaine HCl Via Instillation0/15 (0%)0/15 (0%)15/15 (100%)
Bupivacaine HCl Via Injection0/15 (0%)0/15 (0%)14/15 (93.3%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventBupivacaine HCl Via InstillationBupivacaine HCl Via Injection
NauseaGastrointestinal disorders10/1510/15
VomitingGastrointestinal disorders9/156/15
HeadacheNervous system disorders3/153/15
TachycardiaCardiac disorders3/151/15
HypotensionVascular disorders3/153/15
RhinorrhoeaRespiratory, thoracic and mediastinal disorders2/150/15
ConstipationGastrointestinal disorders2/151/15
Dermatitis contactSkin and subcutaneous tissue disorders1/152/15
Pruritus generalisedSkin and subcutaneous tissue disorders2/151/15
DizzinessNervous system disorders1/151/15

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bupivacaine HCI Via InstillationBupivacaine HCI Via InjectionTotal
<=18 years000
Between 18 and 65 years151530
>=65 years000
Age, Continuous
Age, Continuous(years)Bupivacaine HCI Via InstillationBupivacaine HCI Via InjectionTotal
Mean28.2 ± 6.6732.8 ± 6.5330.5 ± 6.89
Sex: Female, Male
Sex: Female, Male(Participants)Bupivacaine HCI Via InstillationBupivacaine HCI Via InjectionTotal
Female151530
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bupivacaine HCI Via InstillationBupivacaine HCI Via InjectionTotal
Hispanic or Latino9615
Not Hispanic or Latino6915
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Bupivacaine HCI Via InstillationBupivacaine HCI Via InjectionTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American123
White121224
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Bupivacaine HCI Via InstillationBupivacaine HCI Via InjectionTotal
United States151530
08

Study locations

1 site
  • Hermann Drive Surgical Hospital
    Houston, Texas 77027, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Oct 2018, 0 months.

Results were first posted in Oct 2026, 8 years after primary completion.

Of 542 phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2018
First posted
Oct 15, 2018
StartActual
Sep 19, 2018
Primary completionActual
Oct 8, 2018
CompletionActual
Nov 5, 2018
Results first posted
Oct 28, 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 28, 2026
Interventions
Arms added: Bupivacaine HCI via instillation·Bupivacaine HCI via injection; arms removed: Treatment Group 1·Treatment Group 2
Oct 28, 2026
Primary outcomes
6 added, 6 removed
What changed in the outcomes
  • AddedCmaxTime frame: Through 72 hours after start of study drug administration
  • AddedAUClastTime frame: Through 72 hours after start of study drug administration
  • AddedAUCinfTime frame: Through 72 hours after start of study drug administration
  • AddedTmaxTime frame: Through 72 hours after start of study drug administration
  • AddedλzTime frame: Through 72 hours after start of study drug administration
  • Addedt1/2elTime frame: Through 72 hours after start of study drug administration
  • RemovedMaximum Observed Plasma Concentration (Cmax)Time frame: Baseline through 72 hours after start of study drug administration
  • RemovedArea Under the Concentration-time Curve From Time 0 to the Last Collection Time After Study Drug Administration (AUC Last)Time frame: Baseline through 72 hours after start of study drug administration
  • RemovedArea Under the Concentration-time Curve From Time 0 to Infinity After Study Drug Administration (AUC∞)Time frame: Baseline through 72 hours after start of study drug administration
  • RemovedTime to Maximum Plasma Concentration (Tmax)Time frame: Baseline through 72 hours after start of study drug administration
  • RemovedThe Apparent Terminal Elimination Rate Constant (λz)Time frame: Baseline through 72 hours after start of study drug administration
  • RemovedThe Apparent Terminal Elimination Half-life (t1/2el)Time frame: Baseline through 72 hours after start of study drug administration
Oct 28, 2026
Documents
Show all 1 update
  1. Oct 28, 2026
    Results posted
    Primary outcomes 6 added, 6 removed
    What changed in the outcomes
    • AddedCmaxTime frame: Through 72 hours after start of study drug administration
    • AddedAUClastTime frame: Through 72 hours after start of study drug administration
    • AddedAUCinfTime frame: Through 72 hours after start of study drug administration
    • AddedTmaxTime frame: Through 72 hours after start of study drug administration
    • AddedλzTime frame: Through 72 hours after start of study drug administration
    • Addedt1/2elTime frame: Through 72 hours after start of study drug administration
    • RemovedMaximum Observed Plasma Concentration (Cmax)Time frame: Baseline through 72 hours after start of study drug administration
    • RemovedArea Under the Concentration-time Curve From Time 0 to the Last Collection Time After Study Drug Administration (AUC Last)Time frame: Baseline through 72 hours after start of study drug administration
    • RemovedArea Under the Concentration-time Curve From Time 0 to Infinity After Study Drug Administration (AUC∞)Time frame: Baseline through 72 hours after start of study drug administration
    • RemovedTime to Maximum Plasma Concentration (Tmax)Time frame: Baseline through 72 hours after start of study drug administration
    • RemovedThe Apparent Terminal Elimination Rate Constant (λz)Time frame: Baseline through 72 hours after start of study drug administration
    • RemovedThe Apparent Terminal Elimination Half-life (t1/2el)Time frame: Baseline through 72 hours after start of study drug administration
    Interventions Arms added: Bupivacaine HCI via instillation·Bupivacaine HCI via injection; arms removed: Treatment Group 1·Treatment Group 2
    + 2 other changes: conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03705065
Lead sponsor
Heron Therapeutics
Responsible party
Sponsor
First posted
Oct 15, 2018
Start date
Sep 19, 2018
Primary completion
Oct 8, 2018
Completion
Nov 5, 2018
Results posted
Oct 28, 2026
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion